Innovent Biologics (Suzhou) Co. Ltd. clinical trials

A subsidiary of Innovent Biologics, Inc.

The registry lists 197 studies whose lead sponsor is Innovent Biologics (Suzhou) Co. Ltd.. 46 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 197. List all 197 → · All Innovent Biologics, Inc. studies →

• IBI3034 Study in Healthy Adults and Patients With Primary IgA NephropathyNot yet recruitingNCT07886476Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI3046 in Participants With Overweight or ObesityRecruitingNCT07809945Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty ArthritisNot yet recruitingNCT07842497Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07754786Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)RecruitingNCT07066098Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI3016 in Japanese ParticipantsRecruitingNCT07838220Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseaseNot yet recruitingNCT07836660Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingNCT07623798Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingNCT07793019Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese ParticipantsNot yet recruitingNCT07765160Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Open-Label Phase in Participants With Multiple MyelomaNot yet recruitingNCT07764861Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye DiseaseRecruitingNCT07265258Phase 4

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI363 Combined With Bevacizumab for Advanced Colorectal CancerRecruitingNCT07722494Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI363 in Subjects With Advanced MelanomaRecruitingNCT06081920Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerRecruitingNCT07122687Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Clinical Trials of IBI3035 in Healthy SubjectsRecruitingNCT07591519Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI3031 in Participants With Thyroid Eye DiseaseRecruitingNCT07622368Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Safety and Preliminary Activity of BI115 in Advanced SCLCRecruitingNCT07559019Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI343 in Combination Therapy for Advanced Malignant Solid TumorsRecruitingNCT07483554Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07483567Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid TumorsNot yet recruitingNCT07612137Phase 1/2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/ObesityRecruitingNCT07469800Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05458219Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose AdministrationRecruitingNCT07554222Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI3033 in Moderate-to-Severe Atopic DermatitisNot yet recruitingNCT07549984Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07330934Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT07399067Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI363 as Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung CancerNot yet recruitingNCT07402070Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid TumorsRecruitingNCT06974812Phase 1/2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI362 in Chinese Adolescents With Obesity or OverweightRecruitingNCT07255209Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingNCT07113262Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionNot yet recruitingNCT07199010

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsNot yet recruitingNCT07124793Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain MetastasesRecruitingNCT07008287

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2RecruitingNCT06931028Phase 3

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic TherapyRecruitingNCT06797297Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingNCT05636215Phase 1/2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung CancerRecruitingNCT06613009Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C MutationRecruitingNCT05504278Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Study of IBI3005 in Subjects with Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT06418061Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI363 in Subjects with Advanced Solid MalignanciesRecruitingNCT06281678Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Phase 1/2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI363 in Subjects With Advanced MalignanciesRecruitingNCT06468098Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced MalignanciesRecruitingNCT05164458Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid TumorsRecruitingNCT05923008Phase 1/2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOPNot yet recruitingNCT05280626Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)Active, not recruitingNCT06937749Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• Study of IBI3016 in People With Mild or Moderate Hypertension PatientsActive, not recruitingNCT07556796Phase 1

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With ObesityActive, not recruitingNCT06862908Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.

• A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive PatientsActive, not recruitingNCT07352969Phase 2

  Sponsor listed in the registry: Innovent Biologics (Suzhou) Co. Ltd.